藍帆醫療(002382.SZ):同意吉威醫療與上海博脈安及上海博暢發生關聯交易
格隆匯 11 月 10日丨藍帆醫療(002382.SZ)公佈,公司第五屆董事會第九次會議決議,審議並通過了《關於新增子公司與關聯方日常關聯交易的議案》;
同意山東吉威醫療製品有限公司(“吉威醫療”)與上海博脈安醫療科技有限公司(“上海博脈安”)發生關聯交易,金額不超過4020萬元。主要內容是吉威醫療向上海博脈安提供研發項目委託加工檢驗技術服務、BA9病理和藥代動力學研究和具有更高效親脂性的雷帕黴素衍生物化學合成工藝可行性研究等。
同意吉威醫療與上海博暢醫療科技有限公司(“上海博暢”)發生關聯交易,金額不超過2050萬元,主要內容是吉威醫療向上海博暢提供研發項目委託加工檢驗技術服務、BA9病理和藥代動力學研究等。
上述關聯交易新增金額總計不超過6070萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.